17 states consider laws restricting biosimilar Rx substitutions

04/1/2013 | Elsevier Business Intelligence

Legislatures in at least 17 states are considering proposals to restrict the substitution of biosimilar drugs for brand-name biologics. Virginia recently passed such a law, and a bill under consideration in Oregon may be the most restrictive.

View Full Article in:

Elsevier Business Intelligence